Recent Updates
Recently added Catalysts
DCTH Positive Sentiment

Delcath Systems to Participate in Upcoming Investor Conferences

Tuesday, October 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Delcath Systems, Inc. announced its participation in two upcoming investor conferences. The UBS Global Healthcare Conference will take place on November 10, 2026, in Palm Beach Gardens, FL, followed by Canaccord Genuity's MedTech Forum on November 11, 2026, in New York, NY. This engagement highlights the company's focus on interventional oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Delcath Systems is actively engaging with investors.
  • Participation in major healthcare conferences is planned.
  • Focus on treatment for liver cancers is emphasized.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
26%
average across 3 past catalysts
Lead asset
Hepzato Kit (melphalan HDS)
Phase 2 · Refractory Metastatic Colorectal Cancer

Full Press Release Details

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: UBS Global Healthcare Conference on Tuesday, November 10, 2026 in Palm Beach Gardens, FL Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, November 11, 2026 in New York, NY Craig-Hallum A

Frequently Asked Questions

Which conferences will Delcath Systems attend?

Delcath Systems will attend the UBS Global Healthcare Conference and Canaccord Genuity's MedTech Forum.

When is the UBS Global Healthcare Conference?

The UBS Global Healthcare Conference is on November 10, 2026.

Where will the Canaccord Genuity Forum be held?

The Canaccord Genuity Forum will be in New York, NY on November 11, 2026.

What is Delcath Systems focused on?

Delcath Systems focuses on treating primary and metastatic liver cancers.

ShareAdd on Google
Tags: DCTH Delcath Systems investor conferences liver cancer healthcare
Last updated: Oct 27, 2026

Biotech snapshot

Cash runway
$96M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Hepzato Kit (melphalan HDS)Phase 2
Refractory Metastatic Colorectal Cancer →

Catalyst track record

+40%
best trade around DCTH's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for DCTH.

See every catalyst's timing & PoA →